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SUMMARY
There has been no controlled trial of radiotherapy versus
surgery for squamous cell carcinoma of the oesophagus.
Radiotherapy is generally used for those patients with
extensive disease or those who are unfit for surgery. In
spite of this, the 1-year survival of 18 per cent is similar to
that for surgically treated patients and there is no
equivalent operative mortality. The 5-year survival is 6
per cent compared with that for surgery of 4 per cent.
There are no results available to suggest what would
happen if a patient with a localized tumour, technically
suitable for surgical resection, were treated instead by
radiotherapy.
IT is no surprise that radiotherapy has been used for
squamous cell oesophageal carcinoma because squam-
ous skin lesions respond so well. However, since the
classic paper by Pearson in 1966 (1) from Edinburgh
there has been no comparable study nor any subsequent
controlled trial of the results of radiotherapy versus
surgery. In the majority of articles patients have been
selected on a very random basis, either being rejects
from surgery or an incomplete selection from the
community. The results are as difficult to assess as those
for surgical treatment. No radiotherapist appears to
have been given the opportunity to treat early cases of
similar grading to those that do well after surgery.
Nevertheless, an attempt will be made to give mean or
average numbers based on the treatment of all possible
patients in a given population avoiding bias and selec-
tion. The figures obtained from the literature during a
25-year period between 1954 and 1979, amounting to
8489 patients in 49 articles, are set out in Table 1. The
even more controversial problem of the combination of
radiotherapy with surgery has been omitted because of
incomplete evidence.
Methodology
The usual type of radiotherapy is megavoltage.
Kilovoltage is a thing of the past and neutron therapy is
unlikely to be used in the future. The normal equipment
is a linear accelerator, although some centres still use a
cobalt source. Techniques offered are three fields,
opposing fields, rotation and multiple fields. Nobody
knows the optimum dosage, but the minimum dose for
radical treatment is accepted as 5000 rad and the
normally accepted maximum is 6000 rad, above which
unacceptable side effects occur (51). A few centres use
the higher dosage of 6800 rad (37, 52, 53). Of more
importance than the total dose is the daily dose, which
has a range between 175 and 500 rad per day, with a
mean of 200 rad. Since the majority of the Western
world takes two holidays a week, the average treatments
are five per week; therefore the total length of radical
treatment will never be shorter than 3 weeks and may
have to extend to 8. Using a total between 5000 and
6000 rad there exists a great difference in the daily dose
and length of treatment. There is no convincing evid-
ence to show that changing any of these variables within
limits affects the outcome. Nobody has asked the
patient what the optimum span is for himself, but
personal experience of patients undergoing radio-
therapy is that after 4 weeks the patient's morale is low.
If there is nothing to be gained, why spread out the
treatment? Five thousand rad given over 4 weeks in 20
days of treatment at 250 rad each day would appear to
be acceptable to most radiotherapists. No mention has
been made of the biological effects of irradiation on the
tumour because there are not enough details given in the
papers reviewed. However, it is obviously most impor-
tant, being related to the total dose, the number, size and
frequency of treatments and the overall time for the
course of radiotherapy.
Complications
The complications of radiotherapy are mainly those of
morbidity rather than mortality. One reason for the lack
of mortality may be that radiotherapy is stopped if the
patient becomes too ill. In Finland this occurs in 10 per
cent of cases (54). Semantics may also play their part,
since if radical radiotherapy treatment is started, this
converts to palliative if the patient becomes unfit to
complete the course of treatment. Using a neat
syllogism the majority of complications can then be
transferred under the heading of palliation. The true
complications or morbidity of radiotherapy include
skin burns, leucopenia, pulmonary fibrosis and spinal
cord lesions leading to paraplegia. In a modern unit
using properly planned radiotherapy none of these
should occur.
* Part I of this paper, 'A critical review of surgery', appeared in
the June issue.
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% palliative radiotherapy 51+28 (mean + 1 s.d.)
% 1-year survival 18+ 7 (mean +1 s.d.)
% 2-year survival 8 + 6 (mean + 1 s.d.)
% 5-year survival 6 + 6 (mean + 1 s.d.)
Tracheo-oesophageal fistula or aortp-oesophageal
fistula should truly be considered complications of the
disease process itself; the radiotherapy destroys the
cancer cells already extending into the trachea or the
aorta and merely precipitates what is inevitable. This
raises the question as to whether radiotherapy should be
advised when the tumour has infiltrated so far, and this
will be discussed under contraindications. Dysphagia
may get worse at any time during radiotherapy, with a
peak at 5 days (35), but also in the few weeks after the
treatment has finished or at any subsequent time. It is
always difficult to assess why this occurs and whether it
will inevitably happen. The majority of patients gradu-
ally lose their dysphagia during treatment and then
continue to improve; however, up to 50 per cent may
need oesophageal dilatation (35). Those with prolifera-
tive tumours, even though they may be circumferential,
usually have necrosis of the tumour with radiotherapy
and improve rapidly. Those with ulcerated tumours
occupying only part of the wall may suffer oedema and
temporarily increased difficulty. In practice, however, it
is impossible to decide which tumours will get worse
before they get better. Fibrous strictures are probably
not seen for at least 3 months. Re-epithelization of the
oesophagus can take up to a year or more and may
never occur even without there being any dysphagia.
The fibrous strictures can develop with or without the
epithelium having regenerated. Local recurrence after
Oesophageal squamous cell carcinoma 459
adequate radical treatment rarely occurs (54). There is
one study of preoperative radiotherapy, using 5000 rad
2-4 weeks before surgical resection (55), which showed
histological evidence of residual tumour cells at this
stage, so it is clear that the majority of epithelial cancer
cells take a few weeks to die and the process continues
after the treatment has finished. The main effect is to
prevent the growth of the next generation of cells after
mitosis.
Survival
It is difficult to be accurate about these figures because
they involve more patient selection and bias than those
for surgery, and because the majority of patients had
been referred by surgeons as unfit for operation. The
mean figure for 1 -year survival is 18 per cent, 2-year 8
per cent and 5-year 6 per cent. However, in the only
three papers (1,3, 46) out of the total of 49 where the
original population could be compared to that of the
surgical series the figures respectively were 42,46 and 44
per cent for 1-year survival, 8, 15 and 27 per cent for 2-
year and 6, 6 and 20 per cent for 5-year. There is no
study available to show what the results would be if the
most favourable tumours for surgery were actually
treated by radiotherapy instead of operation.
Quality of life
The majority of patients will have their dysphagia
relieved after radical radiotherapy. They will certainly
be able to swallow liquids and their saliva, which is often
more difficult than clear fluid, but it is wrong to suggest
that they will have no difficulty. There is often some
dysphagia with fresh bread and solid meat, even if well
chewed. If patients can eat minced and mashed food
they should be able to sit down to a meal with their
families. When they can swallow this consistency and
have good teeth which they are prepared to use, they
should actually be able to eat normal food. The fact that
the average time interval with dysphagia symptoms
before diagnosis is over 6 months (1, 56, 57) implies that
some of these patients are uninterested in gastronomy,
have a high threshold for abnormal swallowing and are
not worried about this degree of dysphagia. It is unwise
either to dilate or insert a tube into an oesophageal
carcinoma before or during radiotherapy because the
resultant oedema may increase dysphagia and the tube
will fall through later as the tumour regresses. The
majority of patients can manage clear liquids and, with
the development of Aminutrin, Vivonex and Clinifeed,
an adequate calorie intake can be achieved either by
drinking or infusion through a 1 mm bore polyvinyl
tube. There is usually no justification for a nasogastric
tube with its wider bore and greater discomfort, and
there should be no need for parenteral nutrition which
requires intravenous lines, is expensive and not devoid
of complications. Management of subsequent dys-
phagia is essentially similar to that of a benign stricture,
using dilatation to at least 30 FG (10 mm in diameter).
Some strictures can be dilated to 60 FG. Only if the
dilatations are unsuccessful because they have to be
done too frequently is there any need for the insertion of
tubes of the Souttar or Celestin types, but many patients
never need any dilatation at all. Detailed figures are
rarely given as to how frequently a patient needs
dilatation and whether it is dependent on the original
tumour itself or the type of radiation. The reason for this
must lie in the lack of interest radiotherapists have for
mechanical obstructions (very few of the articles written
by radiotherapists have a friendly surgeon or gastro-
enterologist involved). So, if one of the main criti-
cisms of radiotherapy is that the patients may require
subsequent bouginage, this must not be considered an
unsurmountable problem since it can be dealt with by a
specialist. After surgery 30 per cent of the patients need
oesophageal dilatation (58) and this should be com-
pared with an estimated 50 per cent after radiotherapy
(35).
Palliative radiotherapy or none at all?
The difference between radical radiotherapy and pallia-
tive radiotherapy is difficult to judge. One definition is
based on the fact that all patients are submitted to
radical treatment and, if they cannot complete, are then
put into the palliative group. The words curative
radiotherapy are not truly applicable when the 5-year
survival rate is 6 per cent. The problem arises, however,
as to whether all patients with oesophageal squamous
cell carcinoma should be subjected to a radical course of
radiotherapy. Obviously if there is a tracheo-
oesophageal fistula, present in 6-12 per cent
(48, 57, 60), radiotherapy will not help either the symp-
tom of continuous coughing nor the inevitable process
of the disease. This is an extreme example, but the
problem arises as to whether radical radiotherapy is
contraindicated when the tumour is extensive. Only 58
per cent of patients with oesophageal carcinoma are
operable and 39 per cent resectable, leaving 61 per cent
without definitive surgical treatment and the question is
whether radiotherapy should be given in anything other
than palliative doses to those patients with extensive
tumours, with nodes involved far away from the
tumour or with distant metastases. Contraindications to
radiotherapy are discussed by only a few authors
(15, 25, 52, 58). These include age or infirmity, fistulas
and distant metastases. Some authors include pain as an
indication for symptomatic treatment (59) but others
exclude it because it may indicate mediastinal spread
with no possibility for radical treatment (48). Only a
minority of radiotherapy authors consider that indi-
cations should be very exact, avoiding long tumours and
those that might have spread through the adventitia.
There are no papers from which one can obtain
sufficient data, but it appears that the majority of
patients, like those undergoing surgical treatment, have
extensive disease whose natural history cannot be
changed by radiotherapy. Symptomatic therapy is then
indicated, and if dysphagia or pain cannot be improved
by radiotherapy, there would seem no point in using it.
There can be no justification for the indiscriminate use
of radiotherapy.
Conclusion
The facts are incomplete with regard to radiotherapy.
The bias of patient selection is even greater than with
surgery. Many patients are submitted for radiotherapy
having been rejected for an operation, usually because
of extensive disease. There is no epidemiological study
of radiotherapy used on all patients in a community.
There has never been a controlled trial of surgery versus
radical radiotherapy. There has never been a com-
parison of operative resection versus radiotherapy for
those particular tumours which are well treated by both
methods, namely the short tumours less than 5 cm long
with localized disease. In both surgical and radio-
therapy studies the same problem arises, namely the
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management of patients with extensive disease un-
suitable for radical treatment who account for at least
50 per cent of all patients with the condition, and in
these patients symptomatic relief of pain and mecha-
nical obstruction by other methods is most important.
Answers are required to three main questions. Are the
good results of both radiotherapy and surgery entirely
due to the limited extent of that particular original
tumour and unrelated to treatment? If radiotherapy was
used in patients with less extensive disease rather than
those rejected by surgeons, would the results improve
dramatically? If the extent of the tumour could be
assessed, staged and made equal for true comparison, is
radiotherapy better than surgery for improving the
quality and quantity of the remaining years?
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